| LYB |
Report |
Adjusted EBITDA (Total Company) |
BEAT |
pred ~$1.35B vs. cons $1.22B |
MEDIUM |
| LYB |
Report |
Adjusted EPS |
BEAT |
pred ~$1.55 vs. cons $1.35 |
MEDIUM |
| LYB |
Report |
O&P-Americas Segment EBITDA |
BEAT |
pred ~$550M vs. cons $470M |
MEDIUM |
| LYB |
Guide |
Q3 2026 EBITDA/Pricing Momentum Commentary |
LOWER |
guide ~flat-to-down qoq tone vs. cons expecting sequential improvement (Q3 2026) |
MEDIUM |
| LYB |
Guide |
O&P-Americas Utilization/PE-PP Spread Trajectory |
UNCHANGED |
guide ~90% utilization achieved, PE/PP spreads holding near guided levels vs. cons assuming continued spread expansion (Q2 2026 actual / Q3 commentary) |
MEDIUM |
| LYB |
Guide |
I&D Bayport PO/TBA Restart Timing |
UNCHANGED |
guide ~restart completed by quarter-end as promised vs. cons expecting on-time restart (Q2 2026) |
LOW |
| LYB |
Guide |
Capital Allocation / Dividend Policy |
UNKNOWN |
guide ~debt paydown priority maintained, no near-term dividend restoration vs. cons hoping for capital return signal (FY2026) |
LOW |
| LYB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| LYB |
Return |
5-day cumulative residual |
-1.5% (FADE) |
Q2 results likely beat on the Middle East-driven pricing catch-up (PE/PP spreads, Bayport restart), consistent with the Dow/Eastman beat pattern already seen in peers, supporting a positive day-1 pop as LYB re-rates off deeply oversold levels (stock down from $82 ATH to low-$50s before this week's bounce to ~$60 on fresh Iran escalation. However, DOW and OLN's soft Q3 guides (both well below consensus) signal the sell-side will apply the same skepticism to LYB's forward commentary: any hint that PE/PP price gains are decelerating into Q3, or that the Bayport restart benefit is largely already realized, will drive out-period estimate cuts even after a Q2 beat. Given LYB's higher leverage to the same input-cost/pricing dynamics and its own admission of soft APS/auto demand and still-weak Technology licensing, the initial pop is likely to fade over the following days as analysts model a step-down in H2 EBITDA, especially if Middle East risk premium volatility (whipsawing the stock 90% peak-to-trough already this year) proves unstable rather than a durable structural re-rating catalyst. |
LOW |